BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36618343)

  • 1. Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: A Chinese population-based analysis.
    Zhao J; Li D; Xie S; Deng X; Wen X; Li J; Wu Z; Yang X; Li M; Tang Y; Zhang X; Ding Y
    Front Immunol; 2022; 13():1083840. PubMed ID: 36618343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors.
    Chen X; Li Z; Zhou J; Wei Q; Wang X; Jiang R
    PeerJ; 2022; 10():e14566. PubMed ID: 36540802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a nomogram based on common biochemical indicators for survival prediction of children with high-risk neuroblastoma: A valuable tool for resource-limited hospitals.
    Wu R; Li X; Chen Z; Shao Q; Zhang X; Tang W; Hu B
    BMC Pediatr; 2023 Aug; 23(1):426. PubMed ID: 37633889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nomogram Based on Liver Function Test Indicators for Survival Prediction in Nasopharyngeal Carcinoma Patients Receiving PD-1 Inhibitor Therapy.
    Liang L; Li Y; Hong Y; Ji T; Chen H; Lin Z
    Curr Oncol; 2023 Jul; 30(8):7189-7202. PubMed ID: 37623002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
    Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
    Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
    Pires da Silva I; Ahmed T; McQuade JL; Nebhan CA; Park JJ; Versluis JM; Serra-Bellver P; Khan Y; Slattery T; Oberoi HK; Ugurel S; Haydu LE; Herbst R; Utikal J; Pföhler C; Terheyden P; Weichenthal M; Gutzmer R; Mohr P; Rai R; Smith JL; Scolyer RA; Arance AM; Pickering L; Larkin J; Lorigan P; Blank CU; Schadendorf D; Davies MA; Carlino MS; Johnson DB; Long GV; Lo SN; Menzies AM
    J Clin Oncol; 2022 Apr; 40(10):1068-1080. PubMed ID: 35143285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
    Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
    Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Mortality of Patients with Initially Diagnosed Metastatic Cutaneous Melanoma.
    Li W; Xiao Y; Xu X; Zhang Y
    Ann Surg Oncol; 2021 Jul; 28(7):3490-3500. PubMed ID: 33191484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody.
    Yuan S; Xia Y; Shen L; Ye L; Li L; Chen L; Xie X; Lou H; Zhang J
    Cancer Immunol Immunother; 2021 Feb; 70(2):533-546. PubMed ID: 32852602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy.
    Gou M; Qian N; Zhang Y; Wei L; Fan Q; Wang Z; Dai G
    Front Immunol; 2022; 13():950868. PubMed ID: 36225924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
    Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
    Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
    Tian M; Yang J; Han J; He J; Liao W
    Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
    Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
    Front Immunol; 2022; 13():947802. PubMed ID: 36405735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma.
    Sheng Y; Tong L; Geyu L
    Int Immunopharmacol; 2020 Nov; 88():106921. PubMed ID: 32871477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
    Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
    Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer.
    Yang Y; Wang Y; Deng H; Tan C; Li Q; He Z; Wei W; Zhou E; Liu Q; Liu J
    BMC Cancer; 2019 Jun; 19(1):541. PubMed ID: 31170946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
    Wagner NB; Forschner A; Leiter U; Garbe C; Eigentler TK
    Br J Cancer; 2018 Aug; 119(3):339-346. PubMed ID: 29950611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
    Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Establishment and validation of a nomogram to predict overall survival of patients with gastric neuroendocrine neoplasms].
    Wang YL; Guo Y; Zhang RH; Chen LH; Yang YJ; Wang W; Chen J; Zhou ZW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Oct; 24(10):883-888. PubMed ID: 34674463
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.